Table 3.

Headache characteristics and disability at baseline.

Characteristic	Primary analysis (N = 148)
	Before onabotulinumtoxinA	Baseline (before mAb)
Headache frequency (days/month)
Mean (SD)	20.4 (6.6)	14.0 (6.9)
Median (range)	20 (2–30)	12 (0–30)
Change from pre-onabotA, mean (95% CI)		−6.4 (−7.8, −5.1)
Headache days/month, n (%)
≤ 5	3 (2)	10 (6.8)
6–10	4 (2.7)	44 (29.5)
11–14	2 (1.4)	28 (18.2)
15–19	56 (37.8)	29 (19.6)
≥ 20	82 (55.4)	34 (23)
Unknown	1 (0.7)	4 (2.7)

mAb, monoclonal antibody; MHD, monthly headache day; OnabotA, onabotulinumtoxinA; SD, standard deviation.